Receptos Begins Enrollment Of Phase 3 Trial Of RPC1063 In Relapsing Multiple Sclerosis
1/7/2014 9:47:59 AM
SAN DIEGO, Jan. 6, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. announced today that the Company has enrolled the first patients in the Phase 3 portion of RADIANCE, its Phase 2/3 study of RPC1063 in relapsing multiple sclerosis (RMS). The announcement follows the review of interim analysis of the Phase 2 portion of the study which was announced in December 2013.
Help employers find you! Check out all the jobs and post your resume.
comments powered by